SavedAdd your journal

Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı:

Anti-VEGF Treatment Strategiesfor Wet Age Related MacularDegeneration

Yaş Tip Yaşa BağlıMaküla DejeneresansındaAnti-VEGF'lerinUygulama Rejimleri

Nurten ÜNLÜ
Pages
243–249
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This paper will review currently available anti-VEGF agents and evidencebased treatment strategies

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Anti-vascular endothelial growth factor was revolutionized the treatment of wet age related macular degeneration.
📊
Key Findings & Data:Anti-vascular endothelial growth factor was revolutionized the treatment of wet age related macular degeneration.
💡
Conclusion & Impact:This paper will review currently available anti-VEGF agents and evidencebased treatment strategies
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Anti-vascular endothelial growth factor was revolutionized the treatment of wet age related macular degeneration. This paper will review currently available anti-VEGF agents and evidencebased treatment strategies

Özet

Anti-vasküler endotelyal büyüme faktörü (Anti VEGF) yaş tip yaşa bağlı maküla dejenerasyonunun tedavisini tamamıyla değiştirmiştir. Bu derlemede günümüzde tedavide kullanılan antiVEGF ajanlar ve kanıta dayalı tedavi rejimleri tartışılmıştır

🔖

Cite This Article

ÜNLÜ, N. (2022). Anti-VEGF Treatment Strategiesfor Wet Age Related MacularDegeneration. Retina-Vitreus, Cilt: 23 - Sayı:, 243–249. https://ajindex.com/articles/589175

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900.
  2. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration. Ophthalmology 2008;115:1837-46
  3. Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibiti- on Study in Ocular Neovascularization Clinical Trial Group. Pegapta- nib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
  4. Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group. Ranibi- zumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
  5. Arias L, Roman I, Masuet-Aumatell C, et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relations- hip with the number of injections. Retina 2011;31:1261-7. Brand CS. Management of retinal vascular disease: a patient centric app- roach. Eye 2012;26:1-16.
  6. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
  7. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30.
  8. Martin DF, Maguire MG, Ying GS, et al. CATT Research Group. Ranibi- zumab and bevacizumab for neovascular age-related macular degenera- tion. N Engl J Med 2011;364:1897-908.
  9. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration two-year results Ophthalmology 2012;119:1388-98.
  10. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
  11. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Beva- cizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120:2300-9.
  12. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or beva- cizumab in patients with neovascularage-related macular degeneration. Br J Ophthalmol 2013;97:266-71.
  13. Heier JS, Brown DM, Chong V et al. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macula